Everyday Health3h
RSV Vaccine: What You Need to Know
Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...
GlobalData on MSN1d
GSK gains approval in Japan for extended indication of RSV vaccine
GlaxoSmithKline (GSK) has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its regulatory ...
GSK's RSV vaccine gets Japan approval for adults aged 50 to 59
GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in ...
Optimistic Buy Rating for GlaxoSmithKline: Undervalued Stock with Promising Growth Prospects
GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Smith from ...
Business Wire1mon
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...
FiercePharma27d
GSK tries to steady the ship as Arexvy sales plummet in wake of CDC guidance changes
For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales. After a stunning ascension to blockbuster status in its RSV ...
Pharmabiz3d
Japan’s MHLW grants expanded indication approval to GSK’s RSV vaccine, Arexvy for adults aged 50-59 at increased risk of severe RSV disease
GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication of Arexvy (respiratory syncytial virus vaccine, recombinant ...
The American Journal of Managed Care1mon
GSK's Arexvy Vaccine Shows Strong Efficacy Against RSV in Older Adults
Arexvy shows 62.9% efficacy against RSV-LRTD over three seasons in adults aged 60 and older. The vaccine demonstrates 67.4% efficacy against severe RSV-LRTD, with consistent safety data.
Seeking Alpha1mon
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...
London South East4d
GSK's Arexvy approved for wider age range in Japan
(Sharecast News) - Biopharma giant GSK has announced that Japanese regulators have expanded the approved use of its Arexvy vaccine for severe respiratory syncytial virus (RSV) disease to a wider ...
Nasdaq4d
GSK announces Japan’s MHLW approved application to extend indication of Arexvy
GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV disease to ...
Nasdaq4d
GSK Plc Announces Regulatory Expansion For Arexvy In Japan To Include Adults Aged 50-59
(RTTNews) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV ...